Can BİÇMEN, Özlem ŞENGÖREN, Ceyda Mahleç ANAR, Tuba İNAL, İpek ÜNSAL, Hüseyin HALİLÇOLAR

Chronıc obstructıve pulmonary dısease: systemıc ınflammatıon and pulmonary hypertensıon

KOAH, sistemik dolaşımda inflamatuvar mediatörlerin artmasıyla ilişkili bir sistemik hastalıktır. Ancak KOAH'a sekonder oluşan pulmoner hipertansiyonda (PH) potansiyel olarak rol alan ve sistemik inflamasyon yapan mediatörün henüz ne olduğu açık değildir. Çalışmamızda PH olan ve olmayan KOAH hastalarında serum C-reaktif protein (CRP), Tümör nekrozis faktör- (TNF-α ), interlökin-6 (IL-6)' nın sistemik inflamasyondaki rolünü araştırdık.65 KOAH hastası çalışmaya alındı. Solunum fonksiyon testi body pletismograf ile ölçüldü. Pulmoner arter basınçları (PAB) transtorasik ekokardiyografi ile değerlendirildi. Hastaları PH olmayan (PAB 35 mmHg) olarak ikiye ayırdık. Nutrisyonel parametreler olarak Vücut Kitle İndeksi, Triceps Kalınlığı ölçüldü. Serum TNF-α, IL-6 düzeyi ELİSA, CRP düzeyi ise otomatize Immage (Beckman Coulter, A.B.D.) analizörü ile nefelometrik olarak incelendi.PH 1 8 hastada mevcut iken 47 hastada saptanmadı. PH olan KOAH hastaları ile PH olmayan KOAH hastaları karşılaştırıldığında serum CRP, TNF-α , IL-6 düzeyleri arasında istatistiksel olarak anlamlı fark bulunmadı. PH olan KOAH'lılar da FEV1 değeri PH olmayanlara göre istatistiksel olarak anlamlı derecede daha düşük bulundu. PH olan hastalarda parsiyel oksijen basıncı PH olmayanlara göre daha düşük saptandı.KOAH hastalarında artan sistolik pulmoner arter basıncı serum CRP, TNF-α , IL-6 düzeyleri ile ilişkili bulunmadı. Bu nedenle KOAH hastalarında gelişen PH patogenezinde serum CRP, TNF-α , IL-6 gibi inflamatuvar mediatörlerin rolü konusunun açıklığa kavuşturulması için daha detaylı ve hasta sayısının artırılarak yapılacak olan çalışmalara ihtiyaç vardır.

Kronik obstrüktif akciğer hastalığı: sistemik inflamasyon ve pulmoner hipertansiyon

Chronic Obstructive Pulmonary Disease (COPD) is a systemic disease associated with increase of inflammatory mediators in systemic circulation. However, it is not clear yet what the mediator is that potentially takes role in pulmonary hypertension (PH) forming secondary to COPD and leads to systemic inflammation. In this study, we examined the role of serum C-reactive protein (CRP), Tumor necrosis factor- (TNF-α ), and interleukin-6 (IL-6) in COPD patients with and without PH.65 COPD patients were studied. Pulmonary function test was measured by body plethysmograph. Pulmonary artery pressures (PAP) were evaluated by Dopler echocardiography. We divided the patients as with PH (PAP >35 mmHg) and without PH (PAP

PDF

___

1. Barbera JA, Peinado VI, Santos S. Pul monary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 892-905.
2. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005; 60: 605-9.
3. Peinado VI, Barberá JA, Abate P, Ramírez J, Roca J, Santos S, Rodriguez-Roisin R. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1605-11.
4. Stevens T, Janssen PL, Tucker A. Acute and long-term TNF-α administration increases pulmonary vascular reactivity in isolated rat lungs. J Appl Physiol 1992; 73: 708-12.
5. Fujita M, Shannon JM, Irvin CG, Fagan KA, Cool C, Augustin A, Mason RJ. Overexpression of tumor necrosis factor-α produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 280: L39-L49.
6. Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, Peschon JJ, Brody AR, Lungarella G, Friedman M. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Exp Lung Res 1998; 24: 721-43
7. Miyata M, Sakuma F, Yoshimura A, Ishikawa H, Nishimaki T, Kasukawa R. Pulmonary hypertension in rats: 2. Role of interleukin-6. Int Arch Allergy Immunol 1995; 108: 287–91.
8. Gan WQ, Man SFP, Senthilselvan A, Sinn DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a metaanalysis. Thorax 2004; 59: 574-80.
9. Pinto-Plata VM, Mu ̈ llerova H, Toso JF, et al. C-reactive protein in patients with COPD, control smokers, and nonsmokers. Thorax 2006; 61: 1-3.
10. Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, Shale DJ. Inflamm atory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1414-8.
11. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
12. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (suppl): 40S-47S.
13. MacNee W. Pulmonary and systemic oxidant/ antioxidant imbalance in chronic pulmonary disease. Proc Am Thorac Soc 2005; 2: 50-60.
14. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin- 1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-31.
15. Ziesche R, Petkov V, Williams J, Zakeri SM, Mosgöller W, Knöfler M, Block LH. Lipopolysaccharide and interleukin 1 augment the effects of hypoxia and inflammationin human pulmonary arterial tissue. Proc Natl Acad Sci USA 1996; 93: 12478-83.
16. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006; 130: 326-33.
17. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I.. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-41.
18. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 1890-6.
19. Langer F, Schramm R, Bauer M, Tscholl D, Kunihara T, Schäfers HJ. Cytokine response to pulmonary thromboendarterectomy. Chest 2004; 126: 135-41.
20. Kimura H, Okada O, Tanabe N, Tanaka Y, Terai M, Takiguchi Y, Masuda M, Nakajima N, Hiroshima K, Inadera H, Matsushima K, Kuriyama T. Plasma monocyte chemo- attractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 319-24.
21. Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, Sumiya M, Yokohari R. Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 1999; 26: 2357-62.
22. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, Maitre B, Housset B, Brandt C, Le Corvoisier P, Weitzenblum E, Eddahibi S, Adnot S. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136: 678-87.
23. Currie PJ, Seward JB, Chan KL, Fyfe DA, Hagler DJ, Mair DD, Reeder GS, Nishimura RA, Tajik AJ. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985; 6: 750-6.
24. Tramarin R, Torbicki A, Marchandise B, Laaban JP, Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. Eur Heart J 1991; 12: 103-11.
25. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, Pochettino A, Kotloff RM. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-40